CV Sciences (CVSI) EPS (Diluted) Growth (3y) (2020 - 2026)
CV Sciences (CVSI) EPS (Diluted) Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 50.12% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 6.26% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -70.43% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 6.24% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -6.96% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 64.19% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -18.62% |
| 10 | CV Sciences | 3.74 Mn | 3.43 Mn | 1.56 Mn | -27.89% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.89% |
| Dec 31, 2025 | 27.08% |
| Sep 30, 2025 | 33.46% |
| Jun 30, 2025 | 62.28% |
| Mar 31, 2025 | 68.03% |
| Dec 31, 2024 | 68.17% |
| Sep 30, 2024 | -89.68% |
| Jun 30, 2024 | 53.08% |
| Mar 31, 2024 | 49.51% |
| Dec 31, 2023 | 60.70% |
| Sep 30, 2023 | 54.93% |
| Jun 30, 2023 | 43.53% |
| Mar 31, 2023 | 39.46% |
| Dec 31, 2022 | 37.40% |
| Sep 30, 2022 | 26.77% |
| Jun 30, 2022 | -66.27% |
| Mar 31, 2022 | 43.17% |
| Dec 31, 2021 | -73.71% |
| Sep 30, 2021 | -26.26% |
| Jun 30, 2021 | -46.71% |